We are developing GLM101, a novel substrate replacement therapy for PMM2-CDG, a congenital disorder of glycosylation.
2 - 10
π° Series B on 2021-06
Yesterday
2 - 10
Oversee clinical operations for Glycomine's therapeutic programs across multiple trials.